1-3 of 3
Jan Bole
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase I Trial of the Small Molecule Pan-Bcl-2 Family Inhibitor GX15-070 Administered Intravenously (IV) Every 3 Weeks to Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL).

Susan O’Brien, MD, Thomas J. Kipps, MD, Stefan Faderl, MD, Michael Crump, MD, Michael J. Keating, MD, Blanche Anderson, Claudia Soho, Jan Bole, Ruth Turner, Jean Viallet, MD, Bruce D. Cheson, MD
Journal: Blood
Blood (2005) 106 (11): 446.
https://doi.org/10.1182/blood.V106.11.446.446
Published: 2005
Journal Articles

A Phase I/II Trial of Xcellerated T Cells™ in Patients with Chronic Lymphocytic Leukemia.

Januario E. Castro, MD, William G. Wierda, MD, PhD, Thomas J. Kipps, MD, PhD, Michael J. Keating, MBBS, Jan Bole, RN, Blanche Anderson, Jayne Meyer, RN, Mark Bonyhadi, PhD, Ronald J. Berenson, MD, Mark W. Frohlich, MD
Journal: Blood
Blood (2004) 104 (11): 2508.
https://doi.org/10.1182/blood.V104.11.2508.2508
Published: 2004
Journal Articles

Rituximab® and High Dose Methylprednisolone (HDMP) for the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.

Januario E. Castro, M.D., Jan Bole, R.N., Carlos E. Prada, M.D., Thomas J. Kipps, M.D., Ph.D.
Journal: Blood
Blood (2004) 104 (11): 2518.
https://doi.org/10.1182/blood.V104.11.2518.2518
Published: 2004